Impact of human serum albumin on oritavancin in vitro activity against enterococci

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2687-2689

  McKay, Geoffrey A ^a   Beaulieu, Sylvain ^a   Sarmiento, Ingrid ^a   Arhin, Francis F ^a   Parr Jr , Thomas R ^a   Moeck, Gregory ^a  

^a Targanta Therapeutics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; HUMAN SERUM ALBUMIN; LINEZOLID; ORITAVANCIN; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONCENTRATION RESPONSE; DRUG APPROVAL; DRUG PROTEIN BINDING; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS; GLYCOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; SERUM ALBUMIN;

EID: 67049134630     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00197-09     Document Type: Article

References (15)

1. Arhin, F. F., I. Sarmiento, A. Belley, G. A. McKay, D. C. Draghi, P. Grover, D. Sahm, T. R. Parr, Jr., and G. Moeck. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces-implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603.
2. Arhin, F. F., I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2008. Binding of oritavancin to surfaces impacts choice of vessels for oritavancin in vitro assays, abstr. B2. 58th Annu. Meet. Can. Soc. Microbiol. Canadian Society of Microbiologists, Calgary, Canada.
3. Bailey, E. M., M. J. Rybak, and G. W. Kaatz. 1991. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob. Agents Chemother. 35:1089-1092.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 7th ed. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing, 18th information supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Fetterly, G. J., C. M. Ong, S. M. Bhasvnani, J. S. Loutit, S. B. Porter, L. G. Morello, P. G. Ambrose, and D. P. Nicolau. 2005. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. 49:148-152.
7. Hartman, C. S., M. M. Wasilewski, and B. M. Bates. 2008. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combined results of two phase 3 multinational trials, abstr. L-1414. Prog. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother./Infect. Dis. Soc. Am. 46th Annu. Meet. American Society for Microbiology, Washington, DC.
8. McKay, G. A., S. Beaulieu, A. Belley, F. F. Arhin, T. R. Parr, Jr., and G. Moeck. 2007. In vitro time-kill experiments of oritavancin against drugresistant isolates of Staphylococcus aureus and enterococci, abstr. E-1614. Prog. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. McKay, G. A., S. Beaulieu, I. Sarmiento, F. F. Arhin, D. Moraitis, T. R. Parr, Jr., and G. Moeck. 2008. Impact of human serum albumin (HSA) on oritavancin (ORI) in vitro activity against enterococci, abstr. C1-3835. Prog. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. National Committee of Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents, approved guideline. NCCLS document M26-A. National Committee of Clinical Laboratory Standards, Wayne, PA.
11. Rowe, P. A., and T. J. Brown. 2001. In vitro protein binding of [14C]oritavancin in human plasma at 1, 10 and 91 μg/ml employing a dextran coated charcoal adsorption method, abstr. 2193. Prog. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
12. Tsuji, B. T., S. N. Leonard, P. R. Rhomberg, R. N. Jones, and M. J. Rybak. 2008. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn. Microbiol. Infect. Dis. 60:441-444.
13. Van Bambeke, F., Y. Van Laethem, P. Courvalin, and P. M. Tulkens. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936. (Pubitemid 38608472)
14. Zeitlinger, M. A., R. Sauermann, F. Traunmuller, A. Georgopoulos, M. Muller, and C. Joukhadar. 2004. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J. Antimicrob. Chemother. 54:876-880.
15. Zhanel, G. G., I. D. C. Kirkpatrick, D. J. Hoban, A. M. Kabani, and J. A. Karlowsky. 1998. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2427-2430. (Pubitemid 28420391)